Myeloma Therapy

by Lonial, Sagar, M.D.

• ISBN13: 9781934115824
• ISBN10: 1934115827
• Edition: 1st
• Format: Hardcover
• Copyright: 2009-02-28
• Publisher: Humana Pr Inc

Summary

Therapeutic options for patients with myeloma have radically changed over the past ten years. Beginning with the advances in therapy resulting from the use of high dose therapy and autologous bone marrow or stem cell transplant, we have more than doubled the median survival for patients as a whole, and have now a wealth of different biology based treatment approaches for our patients in all disease stages. The purpose of this book is to update the various treatment options for patients with myeloma, as well as to focus on the emerging and speculative aspects of myeloma therapy. This will require review of basic mechanisms of disease as well as further discussions on how these mechanisms can best be targeted. While there will be text covering most areas of myeloma therapy, the prime focus of the book will be the novel agents currently in testing as well as potential future novel targets and agents.

Table of Contents

Biologic Consideration and Myeloma
Staging in Multiple Myeloma	p. 3
Epidemiology of Multiple Myeloma	p. 9
Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment	p. 23
Biology-Based Classification and Staging of Multiple Myeloma	p. 41
Cytogenetic Abnormalities in Multiple Myeloma: The Importance of FISH and Cytogenetics	p. 57
Historical and Cytotoxic Agent-Based Therapies for Myeloma
Role of Autologous Stem Cell Transplantation in Multiple Myeloma	p. 79
Maintenance Therapy in Multiple Myeloma	p. 91
Therapy for Patients not Eligible for Autologous Transplant	p. 99
Current Role of Anthracyclines in the Treatment of Multiple Myeloma	p. 113
Immune-Based Therapies
Allogeneic Transplantation for Multiple Myeloma	p. 125
Immunobiology and Immunotherapy of Multiple Myeloma	p. 143
Antibody and Other Immune-Based Therapies for Myeloma	p. 167
Existing Novel Agents
Thalidomide in Patients with Relapsed Multiple Myeloma	p. 229
Thalidomide: Induction Therapy	p. 229
The Role of Bortezomib in the Treatment of Relapsed and Refractory Multiple Myeloma	p. 239
Bortezomib as Induction Therapy in Patients with Multiple Myeloma	p. 253
Lenalidomide in Relapsed or Refractory Multiple Myeloma	p. 265
Lenalidomide for Initial Therapy of Newly Diagnosed Multiple Myeloma	p. 279
Current and Future Targets
The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma	p. 291
The PI3 Kinase/Akt Pathway as a Therapeutic Target in Multiple Myeloma	p. 309
The Mammalian Target of Rapamycin and Multiple Myeloma	p. 323
CDK Inhibitors in Multiple Myeloma	p. 331
Fibroblast Growth Factor Receptor 3 and Multiple Myeloma	p. 365
Histone Deacetylase Inhibitors in Multiple Myeloma	p. 379
Death Receptors in Multiple Myeloma and Therapeutic Opportunities	p. 393
Proteasome Inhibitors as Therapy in Multiple Myeloma	p. 421
Supportive Care
Pathophysiology of Bone Disease in Multiple Myeloma	p. 435
Anemia and Erythropoeitic Growth Factors in Multiple Myeloma	p. 455
Percutaneous Vertebroplasty and Balloon Kyphoplasty for the Treatment of Acute Painful Pathologic and Nonpathologic Fractures	p. 469
The Role of Anatomic and Functional Imaging in Myeloma	p. 491
Management of Multiple Myeloma Patients with Renal Dysfunction	p. 499
Other Plasma Cell Disorders
Waldenstrom's Macroglobulinemia	p. 519
AL (Immunoglobulin Light-Chain) Amyloidosis	p. 551
POEMS Syndrome and Other Atypical Plasma Cell Disorders	p. 571
Monoclonal Gammopathy of Undetermined Significance	p. 625
Index	p. 651
Table of Contents provided by Blackwell. All Rights Reserved.